{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-010711","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.978604+00:00","generated_at":"2026-05-27T01:38:22.327300+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada acquires Sepranolone for €3M; Phase 2b-ready for Tourette syndrome","bullets":["Acquired Sepranolone (GAMSA neurosteroid) from Asarina Pharma AB for €3 million; €2.756M due within 10 business days.","Phase 2a data: 28% reduction in tic severity (YGTSS, p=0.051); 69% greater quality-of-life improvement vs standard of care.","Phase 2b-ready asset for Tourette syndrome and other compulsive disorders; no CNS off-target effects in Phase 2a.","Relmada to host investor update on next development steps later in 2025.","Deal includes full global ownership rights; Asarina retains pre-closing liabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-010711","json":"https://secwatch.observer/filing/0001213900-25-010711.json","markdown":"https://secwatch.observer/filing/0001213900-25-010711.md","text":"https://secwatch.observer/filing/0001213900-25-010711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025010711/0001213900-25-010711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390025010711/ea0230164-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:38:22.327300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}